X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to fund the continued research and development of company's pipeline, including IMA-203, an adoptive T-cell therapy targeting PRAME (preferentially expressed antigen in melanoma).
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 17, 2024
Details:
IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma, a protein frequently expressed in a large variety of solid cancers, it has potential to address a broad cancer patient population.
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma, a protein frequently expressed in a large variety of solid cancers, it has potential to address a broad cancer patient population.
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
The companies will leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s mRNA technology to develop novel oncology therapies and evaluate Immatics’ investigational IMA203 PRAME TCR-T in combination with Moderna’s investigational PRAME mRNA cancer vaccine.
Lead Product(s): IMA203,PRAME mRNA Vaccine
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: $1,820.0 million Upfront Cash: $120.0 million
Deal Type: Collaboration September 11, 2023
Details:
IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME in HLA-A*02:01-positive patients with PRAME-expressing recurrent and/or refractory solid tumors.
Lead Product(s): IMA402
Therapeutic Area: Oncology Product Name: IMA402
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
The net proceeds will fund the development of Immatics' differentiated platform technologies that are the foundation of its TCR-based cell therapies including, IMA203 and bispecifics.
Lead Product(s): TCR-T Cell Therapy,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 24, 2023
Details:
IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma, a protein frequently expressed in a large variety of solid cancers, it has potential to address a broad cancer patient population.
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
The agreement aims for the most advanced TCR-T candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors using Immatics' XPRESIDENT® technology combined with its XCEPTOR® TCR discovery and engineering platform.
Lead Product(s): TCR-T-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $505.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 01, 2023
Details:
The net proceeds from the offering will be used for working capital and general corporate purposes, including the further development of company's lead product candidate IMA203.
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 10, 2022
Details:
Positively evolving durability profile for IMA203 was observed at higher doses, 6 of 12 patients (50%) treated with more than 1 billion infused TCR-T cells in Phase 1a and Phase 1b cohort A part of trial experienced a confirmed objective response.
Lead Product(s): IMA203,Nivolumab
Therapeutic Area: Oncology Product Name: IMA203
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
